NEW YORK, Dec. 28, 2017 — WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on CLVS, EXEL, CELG, and BCRX which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com revisits the Biotechnology industry, which consists of companies engaged in R&D of new drugs, medical devices, and procedures. The space includes the manufacturing and marketing of drugs because of direct R&D. Under review this morning are the recent performance of Clovis Oncology Inc. (NASDAQ: CLVS), Exelixis Inc. (NASDAQ: EXEL), Celgene Corp. (NASDAQ: CELG), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). All you have to do is sign up today for this free limited time offer, click the link below.
Boulder, Colorado headquartered Clovis Oncology, Inc.'s stock finished Wednesday's session 3.39% higher at $67.17 with a total trading volume of 1.20 million shares. The Company's shares have advanced 12.91% in the last month, 49.10% over the past twelve months, and 51.22% since the start of this year. The stock is trading below its 50-day moving average by 0.38%. Additionally, shares of Clovis Oncology, which focuses on acquiring, developing, and commercializing anti-cancer agents in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 56.42.
On December 19th, 2017, Clovis Oncology announced that the European Union's European Medicines Agency Committee for Medicinal Products for Human Use has requested that the Scientific Advisory Group (“SAG”) on Oncology provide an opinion on aspects of the ongoing Marketing Authorization Application relating to a potential conditional approval for rucaparib. The exact date for the SAG meeting has not yet been set, but the Company expects it to take place in early February 2018. Get the full research report on CLVS for free by clicking below at:
On Wednesday, shares in South San Francisco, California headquartered Exelixis, Inc. recorded a trading volume of 1.97 million shares. The stock ended the session 1.32% higher at $30.81. The Company's shares have advanced 16.79% in the last month, 29.73% in the previous three months, 96.24% over the last twelve months, and 106.64% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 15.69% and 25.94%, respectively. Moreover, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer, have an RSI of 70.04.
On December 19th, 2017, Exelixis announced that the US FDA approved CABOMETYX® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC) – the most common form of kidney cancer in adults. The FDA's priority review and approval of CABOMETYX was based on results from the randomized phase-2 CABOSUN trial in patients with previously untreated RCC, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus sunitinib, a current standard of care. The free technical report on EXEL can be accessed at:
Summit, New Jersey headquartered Celgene Corporation's shares closed the day 2.35% lower at $104.46. The stock recorded a trading volume of 5.96 million shares. The Company's shares have gained 1.09% in the last month. The stock is trading below its 50-day moving average by 2.99%. Additionally, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have an RSI of 47.97.
On December 05th, 2017, Celgene announced the launch of Celgene Cancer Care Links, a new grant program designed to support cancer healthcare capacity building in resource-constrained countries around the world. As part of this program, the Company will collaborate with medical centers focused on enhancing patient care and building sustainable cancer care systems in resource-constrained countries. Funding will be provided to approved programs in 2018.
On December 27th, 2017, research firm Bernstein downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Sign up for free on Wall St. Equities and claim the latest report on CELG at:
Shares in Durham, North Carolina headquartered BioCryst Pharmaceuticals, Inc. finished 1.56% higher at $5.22. The stock recorded a trading volume of 742,740 shares. The Company's shares have advanced 12.50% in the last month. The stock is trading above its 50-day moving averages by 9.72%. Furthermore, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have an RSI of 63.10.
On December 20th, 2017, research firm Barclays initiated an 'Equal Weight' rating on the Company's stock, with a target price of $6 per share. See the free research coverage on BCRX at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Powered by WPeMatico